This study suggested that combined MEK inhibitor with CDK4/6 inhibitor may be clinically more active in NRASmut melanoma patients with concurrent genetic alterations (such as CDKN2A, CDK4, or CCND1) in G1 cell‐cycle checkpoint than MEK inhibition alone. Here, MAP2K7 is linked to melanoma.